Article
Oncology
Yang Li, Jun Cao, Jianfeng Wang, Weidong Wu, Liren Jiang, Xing Sun
Summary: This study found that IGF2BP3 plays an important role in the progression and distant metastasis of breast cancer and is closely associated with brain metastasis. Positive IGF2BP3 expression is related to decreased distant metastasis-free survival and the occurrence of brain metastasis in breast cancer patients. High IGF2BP3 expression is associated with the PD-1 checkpoint pathway, HER2-HER3 signaling, and epithelial-mesenchymal transition.
Article
Oncology
Xueyang Hu, Wenjun Chen, Fanfan Li, Pengfei Ren, Hongyang Wu, Congjun Zhang, Kangsheng Gu
Summary: This study investigated the altered expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and cell proliferation index (Ki-67) in primary and metastatic breast cancer lesions, and their correlation with clinicopathological factors and disease-free survival (DFS). The expression rates of ER, PR, HER2, and Ki-67 were inconsistent between primary and metastatic lesions. The size of the primary lesion was not correlated with altered receptor expression, but lymph node metastasis was. Patients with positive ER and PR expression in both primary and metastatic lesions had the longest DFS, while patients with negative expression had the shortest DFS. Changes in HER2 expression did not affect DFS. Patients with low Ki-67 expression had longer DFS than those with high expression. These findings suggest that the heterogeneity of ER, PR, HER2, and Ki-67 expression has important implications for treatment and prognosis.
FRONTIERS IN ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Yuexin Tong, Shaoqing Xu, Liming Jiang, Chengliang Zhao, Dongxu Zhao
Summary: This study confirms the significance of local surgery in breast cancer patients with bone metastasis and proposes a predictive model to identify optimal surgical candidates.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Oncology
Acharya Balkrishna, Rashmi Mittal, Vedpriya Arya
Summary: This review summarizes the role of miRNA in triple-negative breast cancer, suggesting that miRNA can inhibit metastatic cascade through various mechanisms and may serve as prognostic and metastatic biomarkers.
CURRENT CANCER DRUG TARGETS
(2021)
Review
Biochemistry & Molecular Biology
Misung Park, Dohee Kim, Sunghyub Ko, Ayoung Kim, Kyumin Mo, Hyunho Yoon
Summary: Breast cancer is the most common malignancy in women worldwide, and metastasis is the leading cause of high mortality. Currently, breast cancer is often discovered or diagnosed after metastasis has occurred, resulting in poor prognosis. Understanding the mechanisms and nature of breast cancer metastasis can facilitate the development of targeted therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, Research & Experimental
Xudong Zhu, Jiawen Bu, Tong Zhu, Yi Jiang
Summary: KK-LC-1 is highly expressed in triple-negative breast cancer and is associated with poor prognosis. Silencing KK-LC-1 can inhibit malignant behaviors of triple-negative breast cancer through the MAL2/MUC1-C/PI3K/AKT/mTOR pathway. The small molecule compound Z839878730 can target KK-LC-1 and kill cancer cells effectively.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Amy K. Schulze, Tanya L. Hoskin, Dan Moldoveanu, Jenna L. Sturz, Judy C. Boughey
Summary: This study described the clinicopathologic characteristics and management of bilateral breast cancer (BC) and compared them with unilateral BC. The results showed that bilateral BC patients typically have larger tumors, lobular histology, ER+ status, multicentricity or multifocality, and pathogenic variants, but their disease-free survival is not worse than that of unilateral BC.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Cell Biology
Songjie Shen, Yu Song, Bin Zhao, Yali Xu, Xinyu Ren, Yidong Zhou, Qiang Sun
Summary: The study identified miR-7641 as a key miRNA in cancer-derived exosomes promoting tumor progression and metastasis via intercellular communication. Exosomal miR-7641 may serve as a non-invasive diagnostic biomarker and potential therapeutic target in breast cancer treatment.
CELL COMMUNICATION AND SIGNALING
(2021)
Review
Oncology
Lilan Chen, Chunyan Zhu, Fan Pan, Ying Chen, Lei Xiong, Yan Li, Xiaoyuan Chu, Guichun Huang
Summary: The interplay between platelets and tumors has been extensively studied, with the understanding that platelets can promote tumor metastasis. However, the precise interactions between platelets and tumor cells have not been fully explored. Recent research has focused on platelets in both the circulation and primary tumor microenvironment, revealing their complex roles in tumor development. This review summarizes the biological effects of platelets on tumors, including regulating tumor growth, promoting metastasis, influencing vasculature, evading immune responses, and mediating tumor metabolism and inflammation.
FRONTIERS IN ONCOLOGY
(2023)
Review
Cell Biology
Hongjiang Si, Madelyn Esquivel, Erika Mendoza Mendoza, Kevin Roarty
Summary: Breast cancer is the most commonly diagnosed cancer in women worldwide and is a leading cause of cancer-related deaths. While there have been advancements in treating the primary tumor, systemic treatments to prevent metastasis are still limited. Metastatic disease is the main factor contributing to fatality in breast cancer patients. Understanding the mechanisms driving tumor cell growth, survival, and spread, as well as their interaction with the microenvironment, is crucial for identifying potential therapeutic interventions for metastasis and cancer dormancy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Article
Oncology
Nannan Lu, Changfang Fu, Lei Zhang, Yangyang You, Xiang Li, Qian Zhang, Pin Wang, Xinghua Han
Summary: A prognostic biomarker called LNPRS was developed for breast cancer patients with lymph node metastasis. It was found to be able to predict the overall survival of patients and guide the therapeutic decisions. The LNPRS was also associated with immune cell infiltration and had predictive value for chemotherapy and immunotherapy.
FRONTIERS IN ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Claire L. Ihle, Sabrina J. Wright-Hobart, Philip Owens
Summary: The survival rate of breast cancer patients has improved, but metastatic breast cancer still causes high mortality. Metastasis mainly occurs in the bone, and current treatment methods focus on palliative care and slowing down the progression. Recent advances in molecularly targeted agents have made breakthroughs in the treatment of metastatic breast cancer, but immunotherapies have not been fully applied in estrogen receptor-positive tumors. Therapeutic approaches targeting the bone microenvironment of metastatic breast cancer have potential applications in other bone-resident cancers.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Biochemistry & Molecular Biology
Ganji Seeta Rama Raju, Eluri Pavitra, Sai Samyuktha Bandaru, Ganji Lakshmi Varaprasad, Ganji Purnachandra Nagaraju, Rama Rao Malla, Yun Suk Huh, Young-Kyu Han
Summary: HOTAIR is an oncogenic non-coding RNA that is strongly associated with tumor grade and prognosis in various carcinomas, including breast cancer (BC). It regulates target genes through sponging and epigenetic mechanisms and controls oncogenic cellular and signaling mechanisms, such as metastasis and drug resistance. In BC cells, HOTAIR expression is regulated by transcriptional and epigenetic mechanisms. This review discusses the regulatory mechanisms of HOTAIR during cancer development and explores its role in BC development, metastasis, and drug resistance. The review also highlights the potential therapeutic applications of HOTAIR in BC management, treatment, and prognosis.
Article
Oncology
Jose Pablo Leone, Michael J. Hassett, Julieta Leone, Sara M. Tolaney, Carlos T. Vallejo, Bernardo A. Leone, Eric P. Winer, Nancy U. Lin
Summary: This study compares the proportions of pathologic complete response (pCR) between male breast cancer (MaBC) and female breast cancer (FBC) in neoadjuvant chemotherapy (NAC), and finds that FBC has higher pCR rates. Furthermore, pCR is associated with survival rates in both MaBC and FBC.
Article
Oncology
Idalid Franco, Mohammed Alshalalfa, Alexandra Hernandez, Brandon A. A. Mahal, Tiffany Nguyen, Lora Wang, Rinaa Punglia, Nishwant Swami, Neha Goel
Summary: Breast cancer in younger women is more aggressive and has higher mortality rates compared to older women. The genomic landscape of breast cancers in younger women differs from that of older women, with distinct molecular and genomic characteristics.
ANNALS OF SURGICAL ONCOLOGY
(2023)